View Future GrowthStablecoin Development 過去の業績過去 基準チェック /46Stablecoin Developmentは、平均年間71.8%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.8% 4.1%収益成長率で 減少しています。 Stablecoin Developmentの自己資本利益率は376.4%であり、純利益率は2078.7%です。主要情報71.76%収益成長率126.49%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率-4.12%株主資本利益率376.38%ネット・マージン2,078.65%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Aug 02NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024お知らせ • Nov 03NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023お知らせ • Aug 09NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023お知らせ • May 05NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023お知らせ • Feb 02NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023すべての更新を表示Recent updatesお知らせ • Jan 20NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Sep 12NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025.お知らせ • Aug 28NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025.お知らせ • Aug 22+ 2 more updatesNovabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025On August 19, 2025 and effective at the First Closing, Justin Hall voluntarily resigned as the Chief Executive Officer of the NovaBay Pharmaceuticals, Inc., though he will remain a named executive officer of the Company and serve as the Vice President of Business Development, General Counsel and Corporate Secretary of the Company (as further described in subpart (e) below) as well as a director serving on the Board. Appointment of David Lazar as Chief Executive Officer, Effective Immediately. Mr. Lazar, age 35, previously served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) where he also previously served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Cyclacel Pharmaceuticals, Inc., from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Titan Pharmaceuticals Inc. listed on Nasdaq from August 2022 to April 2024, where he also served as a director and board chairman from August 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. from March 2024 to August 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR House Inc. from October 2024 to April 2025.お知らせ • Aug 20NovaBay Pharmaceuticals, Inc. announced that it expects to receive $6 million in fundingNovaBay Pharmaceuticals, Inc entered into a subscription agreement to issue 481,250 shares of Series D non-voting convertible preferred stock at an issue price of $8 for the proceeds of $3,850,000 and 268,750 shares of Series E non-voting convertible preferred stock at an issue price of $8 for the proceeds of $2,150,000 on August 19, 2025. The transaction involves participation of David E. Lazar as an investor. On the same day, company closed the first tranche of Series D non-voting convertible preferred stock for the proceeds of $3,850,000. The Purchase Agreement also contemplates that Mr. Lazar will separately purchase and acquire 268,750 shares of Series E Preferred Stock as soon as practicable after the Company receives the Conversion Approval subject to shareholder approvalお知らせ • Apr 02NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2025, NovaBay Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 30RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million on October 29, 2024. Refresh’s unsolicitedoffer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh’s unsolicitedoffer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price.お知らせ • Aug 02NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024お知らせ • Jul 27NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,200,380 Price\Range: $1.1 Security Name: Series F-1 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-3 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-2 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380お知らせ • Jul 13Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024NovaBay Pharmaceuticals, Inc. provided revenue guidance for the year 2024. The company expects 2024 net revenue from the Company’s eyecare products to be approximately $10 million.お知らせ • Apr 20NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024, at 11:00 Pacific Daylight. Agenda: To elect three Class II directors nominated by our Board of Directors to hold office for a term of three years or until their respective successors are elected and qualified; to consider ratifying the appointment by our Audit Committee of WithumSmith+Brown, PC as our independent registered public accounting firm; to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of all of our Common Stock issued and outstanding; to grant authorization to our Board of Directors to determine, in its sole discretion, the specific ratio at any whole number within such share range and the timing of the Reverse Stock Split becoming effective or to abandon the Reverse Stock Split; to adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.お知らせ • Mar 26+ 1 more updateNew Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay. New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) on March 25, 2024.お知らせ • Mar 15New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay.お知らせ • Nov 03NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023お知らせ • Aug 09NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023お知らせ • May 19NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023, at 11:00 Pacific Daylight. Agenda: To consider directorate elections; to ratify the appointment by the Audit Committee of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.お知らせ • May 05NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023お知らせ • Feb 02NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023収支内訳Stablecoin Development の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:B9P1 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26255238031 Dec 250-338030 Sep 2510-712030 Jun 2510-912031 Mar 2510-912031 Dec 240-107030 Sep 242-158030 Jun 245-148031 Mar 248-1510031 Dec 2310-1310030 Sep 2312-1512030 Jun 2313-1913031 Mar 2313-1714031 Dec 2214-1615030 Sep 2214-916030 Jun 2213-517031 Mar 2212-517031 Dec 2110-715030 Sep 219-713030 Jun 218-813031 Mar 2110-1112031 Dec 2010-1112030 Sep 2010-1313030 Jun 209-1012031 Mar 207-812031 Dec 197-1014030 Sep 198-815030 Jun 1910-1017031 Mar 1911-919031 Dec 1813-719030 Sep 1815-419030 Jun 1816-520031 Mar 1817-621031 Dec 1718-722030 Sep 1716-1023030 Jun 1715-1122031 Mar 1714-1221131 Dec 1612-1319130 Sep 169-1620230 Jun 167-1720431 Mar 166-1920531 Dec 154-1919630 Sep 153-1915730 Jun 152-18128質の高い収益: B9P1は 高品質の収益 を持っています。利益率の向上: B9P1過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: B9P1過去 5 年間で収益を上げており、収益は年間71.8%増加しています。成長の加速: B9P1は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: B9P1昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 15.3% ) と比較することは困難です。株主資本利益率高いROE: B9P1の 自己資本利益率 ( 376.4% ) は 傑出している と考えられます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 11:46終値2026/02/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stablecoin Development Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Edward WooAscendiant Capital Markets LLCPooya HemamiDesjardins Securities Inc.Christian GlennieEdison Investment Research5 その他のアナリストを表示
お知らせ • Aug 02NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024
お知らせ • Nov 03NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
お知らせ • Aug 09NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023
お知らせ • May 05NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023
お知らせ • Feb 02NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023
お知らせ • Jan 20NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Sep 12NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025.
お知らせ • Aug 28NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025.
お知らせ • Aug 22+ 2 more updatesNovabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025On August 19, 2025 and effective at the First Closing, Justin Hall voluntarily resigned as the Chief Executive Officer of the NovaBay Pharmaceuticals, Inc., though he will remain a named executive officer of the Company and serve as the Vice President of Business Development, General Counsel and Corporate Secretary of the Company (as further described in subpart (e) below) as well as a director serving on the Board. Appointment of David Lazar as Chief Executive Officer, Effective Immediately. Mr. Lazar, age 35, previously served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) where he also previously served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Cyclacel Pharmaceuticals, Inc., from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Titan Pharmaceuticals Inc. listed on Nasdaq from August 2022 to April 2024, where he also served as a director and board chairman from August 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. from March 2024 to August 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR House Inc. from October 2024 to April 2025.
お知らせ • Aug 20NovaBay Pharmaceuticals, Inc. announced that it expects to receive $6 million in fundingNovaBay Pharmaceuticals, Inc entered into a subscription agreement to issue 481,250 shares of Series D non-voting convertible preferred stock at an issue price of $8 for the proceeds of $3,850,000 and 268,750 shares of Series E non-voting convertible preferred stock at an issue price of $8 for the proceeds of $2,150,000 on August 19, 2025. The transaction involves participation of David E. Lazar as an investor. On the same day, company closed the first tranche of Series D non-voting convertible preferred stock for the proceeds of $3,850,000. The Purchase Agreement also contemplates that Mr. Lazar will separately purchase and acquire 268,750 shares of Series E Preferred Stock as soon as practicable after the Company receives the Conversion Approval subject to shareholder approval
お知らせ • Apr 02NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2025, NovaBay Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 30RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million on October 29, 2024. Refresh’s unsolicitedoffer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh’s unsolicitedoffer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price.
お知らせ • Aug 02NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024
お知らせ • Jul 27NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,200,380 Price\Range: $1.1 Security Name: Series F-1 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-3 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380 Security Name: Series F-2 Warrants Security Type: Equity Warrant Securities Offered: 3,200,380
お知らせ • Jul 13Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024NovaBay Pharmaceuticals, Inc. provided revenue guidance for the year 2024. The company expects 2024 net revenue from the Company’s eyecare products to be approximately $10 million.
お知らせ • Apr 20NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024, at 11:00 Pacific Daylight. Agenda: To elect three Class II directors nominated by our Board of Directors to hold office for a term of three years or until their respective successors are elected and qualified; to consider ratifying the appointment by our Audit Committee of WithumSmith+Brown, PC as our independent registered public accounting firm; to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of all of our Common Stock issued and outstanding; to grant authorization to our Board of Directors to determine, in its sole discretion, the specific ratio at any whole number within such share range and the timing of the Reverse Stock Split becoming effective or to abandon the Reverse Stock Split; to adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.
お知らせ • Mar 26+ 1 more updateNew Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay. New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) on March 25, 2024.
お知らせ • Mar 15New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay.
お知らせ • Nov 03NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
お知らせ • Aug 09NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023
お知らせ • May 19NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023, at 11:00 Pacific Daylight. Agenda: To consider directorate elections; to ratify the appointment by the Audit Committee of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters.
お知らせ • May 05NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023
お知らせ • Feb 02NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023